ALMS$6.501.88%0.12
After Hours: 6.56+0.06 +0.92%
Alumis Inc (ALMS)
Date: 2026-11-03 16:00O: 6.41H: 6.61L: 6.22C: 6.50Vol: 2.566M
Alumis Inc stock is traded at $6.50, with a volume of 2,566,386. It is up +1.88% in the last 24 hours and down -5.11% over the past month. Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Previous Close:
$6.38
Open:
$6.41
24h Volume:
2,566,386
Relative Volume:
1.30
Market Cap:
$841.33M
Revenue:
$8.40M
Net Income/Loss:
-$237.42M
P/E Ratio:
-
EPS:
-$1.92
Net Cash Flow:
-$377.03M
1W Performance:
-2.11%
1M Performance:
-5.11%
6M Performance:
-74.19%
1Y Performance:
+42.54%
1-Day Range:
$6.22$6.61
1-Week Range:
$6.22$7.25
52-Week Range:
$4.39$31.35
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis IncSector
HealthcareIndustry
BiotechnologyPhone
650-231-6625Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Upgrades & Downgrades
Alumis Inc Stock (ALMS) Financials Data
Alumis Inc Stock (ALMS) Insider Trading
- AKKARAJU SRINIVASSep 08 '26Director
- Transaction
- Sale
- Cost
- $10.55
- #Shares
- 96,131
- Value ($)
- 1,014,028
- #Shares Total
- 2,025,493
- AKKARAJU SRINIVASSep 08 '26Director
- Transaction
- Buy
- Cost
- $10.63
- #Shares
- 546,581
- Value ($)
- 5,808,571
- #Shares Total
- 4,937,026
- AKKARAJU SRINIVASSep 04 '26Director
- Transaction
- Buy
- Cost
- $11.17
- #Shares
- 440,140
- Value ($)
- 4,917,684
- #Shares Total
- 4,711,801
- Hardiman Roy C.Aug 03 '26Chief Business & Strategy Ofcr
- Transaction
- Sale
- Cost
- $26.37
- #Shares
- 2,692
- Value ($)
- 70,988
- #Shares Total
- 207,746
- Goldstein David MAug 03 '26Chief Scientific Officer
- Transaction
- Sale
- Cost
- $26.37
- #Shares
- 2,596
- Value ($)
- 68,457
- #Shares Total
- 30,970
- Drappa JornAug 03 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $26.37
- #Shares
- 2,447
- Value ($)
- 64,527
- #Shares Total
- 56,892
- Bradley Mark ChristopherAug 03 '26Chief Development Officer
- Transaction
- Sale
- Cost
- $26.37
- #Shares
- 2,572
- Value ($)
- 67,824
- #Shares Total
- 48,533
- Schroer John R.Aug 03 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $26.37
- #Shares
- 3,282
- Value ($)
- 86,546
- #Shares Total
- 24,718
- Pangali SanamAug 03 '26Chief Legal Officer
- Transaction
- Sale
- Cost
- $26.37
- #Shares
- 1,364
- Value ($)
- 35,969
- #Shares Total
- 9,747
- Pangali SanamJul 06 '26Chief Legal Officer
- Transaction
- Option Exercise
- Cost
- $5.06
- #Shares
- 5,000
- Value ($)
- 25,300
- #Shares Total
- 16,111
